Source:http://linkedlifedata.com/resource/pubmed/id/15818505
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0011306,
umls-concept:C0019168,
umls-concept:C0020971,
umls-concept:C0033684,
umls-concept:C0039195,
umls-concept:C0205263,
umls-concept:C0679058,
umls-concept:C0871261,
umls-concept:C1510800,
umls-concept:C1519680,
umls-concept:C1547699,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C2700640,
umls-concept:C2911692
|
| pubmed:issue |
7
|
| pubmed:dateCreated |
2005-6-8
|
| pubmed:abstractText |
Dendritic cells (DC) are specialized antigen-presenting cells with powerful immunostimulatory properties. Their use for induction of anti-tumor immunity has been limited by several factors, including identification of appropriate tumor-associated antigens, delivery of antigens to DC, and maintaining DC in a highly activated state. Here, DC propagated in vitro were transduced with an adenoviral (Ad) vector to express hepatitis B surface antigen (HBsAg), an antigen present in hepatocellular carcinoma (HCC). Many patients with HCC demonstrate evidence of prior HBV exposure, suggesting that the presence of the virus in a quiescent state may promote tumorigenesis. Ad-HBsAg-transduced DC stimulated strong cytotoxic T lymphocyte (CTL) responses to HBsAg-expressing tumor cells, and protected mice from lethal tumor challenge. Immunity was antigen-specific, as wild-type tumor (HBsAg -) grew normally. Furthermore, DC transduced with an irrelevant vector had no effect. Vaccination with HBsAg protein, a clinically utilized preparation that confers immunity to HBV infection, did not protect against tumor challenge even though it induced a strong antibody response. These studies describe for the first time the contributions of humoral and cellular immune responses to tumor immunity induced by Ad-transduced DC compared to protein vaccination.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0171-5216
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
131
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
429-38
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15818505-Adenoviridae,
pubmed-meshheading:15818505-Animals,
pubmed-meshheading:15818505-Antigens, Neoplasm,
pubmed-meshheading:15818505-Cancer Vaccines,
pubmed-meshheading:15818505-Cells, Cultured,
pubmed-meshheading:15818505-Cytotoxicity, Immunologic,
pubmed-meshheading:15818505-Dendritic Cells,
pubmed-meshheading:15818505-Flow Cytometry,
pubmed-meshheading:15818505-Genetic Vectors,
pubmed-meshheading:15818505-Hepatitis B Surface Antigens,
pubmed-meshheading:15818505-Immune Tolerance,
pubmed-meshheading:15818505-Immunity, Cellular,
pubmed-meshheading:15818505-Immunization,
pubmed-meshheading:15818505-Immunotherapy,
pubmed-meshheading:15818505-Male,
pubmed-meshheading:15818505-Melanoma, Experimental,
pubmed-meshheading:15818505-Mice,
pubmed-meshheading:15818505-Mice, Inbred C57BL,
pubmed-meshheading:15818505-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15818505-Transfection
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.
|
| pubmed:affiliation |
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|